Semma Therapeutics Overview

  • Founded
  • 2014

Founded
  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $937M

Semma Therapeutics General Information

Description

Developer of trans-formative therapies designed to eliminate the use of insulin injections for type 1 diabetes patients. The company's trans-formative therapies is a cell-based therapy for diabetes which traditionally requires the use of an invasive insulin pump or multiple daily insulin injections combining proprietary cells with a state-of-the-art device to provide a replacement for the missing beta cells in a diabetic patient without immunosuppression, enabling doctors to provide a functional cure for patients with diabetes.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 100 Technology Square
  • Floor 3
  • Cambridge, MA 02139
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Semma Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 10-Oct-2019 $937M 00000 00000 Completed Generating Revenue
3. Early Stage VC (Series B) 30-Nov-2017 00000 00000 Completed Startup
2. Grant 12-Sep-2016 $5M $44M Completed Startup
1. Early Stage VC (Series A) 24-Mar-2015 $44M $44M 000.00 Completed Startup
To view Semma Therapeutics’s complete valuation and funding history, request access »

Semma Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
To view Semma Therapeutics’s complete cap table history, request access »

Semma Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of trans-formative therapies designed to eliminate the use of insulin injections for type 1 diabetes patients.
Drug Discovery
Cambridge, MA
00000
0000 0000-00-00
000000&0 00000

000000

consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nu
0000000000000
Tucson, AZ
00 As of 0000
000.00
0000 0000-00-00
000000&0 000.00

000000

o laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volupta
0000000000000
London, Canada
00 As of 0000
000.00
00000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Semma Therapeutics Competitors (51)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Calimmune Formerly VC-backed Tucson, AZ 00 000.00 000000&0 000.00
0000000 Corporation London, Canada 00 000.00 00000000 000.00
000000 Venture Capital-Backed Ann Arbor, MI 00 00000 000000 - 000 00000
0000000 Formerly VC-backed Boston, MA 000 00000 000000000 00000
00000000 Formerly VC-backed South San Francisco, CA 00 00000 000000000 00000
You’re viewing 5 of 51 competitors. Get the full list »

Semma Therapeutics Former Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
6 Dimensions Capital Venture Capital Minority 000 0000 000000 0
ARCH Venture Partners Venture Capital Minority 000 0000 000000 0
California Institute for Regenerative Medicine Government 000 0000 000000 0
Cowen Healthcare Investments Venture Capital Minority 000 0000 000000 0
Eight Roads Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »

Semma Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 16-Nov-2015 0000000000 Biotechnology 0000000 0
To view Semma Therapeutics’s complete acquisitions history, request access »